Drug Approval | October 06, 2025
Early stage projects of up to Rs. 9 crore eligible for up to Rs. 5 crore assistance and later stage projects of up to Rs. 285 crore eligible for up to Rs. 100 crore assistance
Investment to expand manufacturing and global medicine supply capacity
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers
Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%
The expansion will significantly enhance AbbVie’s ability to meet growing global demand for biologics, particularly in oncology and immunology
Miels will formally assume the role on January 1, 2026
Subscribe To Our Newsletter & Stay Updated
